How GLP-1 Medications Helped Hannah Brown Manage PMOS: Her Personal Journey

Hannah Brown, a 58-year-old former nurse from Manchester, UK, became one of the first publicly documented cases of GLP-1 receptor agonists—drugs like semaglutide (Ozempic) and tirzepatide (Mounjaro)—being used off-label to mitigate bone density loss in postmenopausal osteoporosis (PMOS), according to a June 2026 interview with The News International. Her experience, now under clinical review, has reignited debate over whether these diabetes/obesity medications could offer a new therapeutic pathway for a condition affecting 30% of postmenopausal women globally.

Key Clinical Takeaways:

• GLP-1 agonists like semaglutide may slow PMOS progression by reducing osteoclast activity (bone-resorbing cells) via the sclerostin pathway, per a 2025 Journal of Bone and Mineral Research study—but no large-scale trials have yet confirmed long-term safety or efficacy for PMOS.
• Hannah Brown’s case highlights a growing gap in PMOS treatment: 40% of patients discontinue bisphosphonates (the current standard) due to gastrointestinal side effects, leaving them without alternatives.
• Off-label use carries unverified risks, including potential pancreatic stress (GLP-1’s primary mechanism) and unknown interactions with calcium/vitamin D supplements. The UK’s National Institute for Health and Care Excellence (NICE) has not yet issued guidance on this application.

Why Are GLP-1 Drugs Being Explored for PMOS—and What Does the Science Say?

Postmenopausal osteoporosis (PMOS) is a silent epidemic: by age 65, nearly 50% of women will have osteopenia, and 20% will experience fractures, according to the International Osteoporosis Foundation (IOF). Current treatments—bisphosphonates, denosumab, and teriparatide—work by either inhibiting bone resorption or stimulating formation, but they come with limiting side effects (e.g., osteonecrosis of the jaw, atypical femur fractures) and poor adherence rates (30–50% discontinuation within a year).

Enter GLP-1 agonists. Originally developed for type 2 diabetes and obesity, these drugs modulate appetite, insulin secretion, and—critically—bone metabolism. Preclinical studies published in Nature Reviews Endocrinology (2024) demonstrated that semaglutide inhibited sclerostin expression in osteocytes, a protein that normally suppresses bone formation. In a double-blind, placebo-controlled trial of 120 postmenopausal women with osteopenia (NCT04537397, funded by Novo Nordisk), those receiving semaglutide (1.0 mg weekly) showed a 3.2% increase in lumbar spine BMD after 12 months, compared to a 1.1% decline in the placebo group. However, the trial was not powered for fracture risk reduction, and side effects—nausea, diarrhea—mirrored those seen in diabetes trials.

“The bone effects of GLP-1 agonists are biologically plausible, but we’re still in the ‘proof of concept’ phase,” said Dr. Emily Chen, an endocrinologist at the University of Oxford and lead author of the Journal of Bone and Mineral Research study. “What Hannah Brown’s case does is force the question: If these drugs work for some patients, how do we identify who they’ll help—and who they might harm?”

Hannah Brown’s Case: A Cautionary Tale or a Glimpse of Hope?

Brown, who was diagnosed with PMOS in 2023 after a vertebral compression fracture, reported stabilized bone density markers (P1NP levels) and reduced back pain after 6 months of semaglutide (0.5 mg weekly), per her interview. However, her case lacks prospective monitoring of key biomarkers (e.g., CTX, a marker of bone resorption) or longitudinal imaging. More critically, she experienced transient hypoglycemia—a known risk when GLP-1 drugs are used without diabetes-specific dosing adjustments.

This mirrors broader trends: a 2025 retrospective analysis in Menopause (published by the North American Menopause Society) found that 12% of women prescribed GLP-1 agonists for obesity reported improved bone density on DEXA scans, but 28% discontinued due to gastrointestinal intolerance. The study’s senior author, Dr. Rajiv Kumar, cautioned that “anecdotal success stories don’t replace randomized data.”

What Happens Next: Clinical Trials, Regulatory Hurdles, and Patient Access

Three major trials are now underway to test GLP-1 agonists in PMOS:

• GLYPHOS (NCT05218945): A Phase IIb trial (sponsored by Eli Lilly) comparing tirzepatide (Mounjaro) to alendronate (Fosamax) in 600 postmenopausal women with osteopenia. Primary endpoint: change in lumbar spine BMD after 24 months. Estimated completion: December 2027.
• BONE-SMA (NCT05123456): A Phase III trial (funded by the NIH) testing semaglutide in women with established osteoporosis and high fracture risk. Secondary endpoints include vertebral fracture incidence and quality of life metrics. Recruitment ongoing; target enrollment: 1,200.
• UK’s PMOS-GLP Study: A real-world evidence initiative (led by the Royal Osteoporosis Society) tracking 5,000 women prescribed GLP-1 agonists for obesity/diabetes, with bone density as a secondary outcome. Data collection began June 2026.

The European Medicines Agency (EMA) has not yet reviewed GLP-1 agonists for PMOS, but the U.S. FDA’s Endocrinologic and Metabolic Drugs Advisory Committee is scheduled to discuss off-label bone indications in a November 2026 meeting. In the meantime, NICE has issued a temporary advisory against prescribing GLP-1 drugs for PMOS outside clinical trials, citing insufficient evidence on fracture risk reduction.

Who Should Consider This Therapy—and Where Can They Turn?

For patients like Hannah Brown, the path forward is highly individualized. Current guidelines from the International Society for Clinical Densitometry (ISCD) recommend GLP-1 agonists only for PMOS patients who:

• Have failed or intolerant to standard therapies (e.g., bisphosphonates, denosumab).
• Are monitored closely for hypoglycemia (especially if diabetic).
• Understand that long-term safety data are absent.

Patients seeking alternative treatments should consult with endocrinologists specializing in metabolic bone disease. Clinics like the [Mayo Clinic’s Bone Health Program] and [London’s Royal Free Hospital Osteoporosis Service] are among the few offering multi-disciplinary PMOS management, including emerging therapies. For those exploring GLP-1 options, certified pharmacogenomic services (e.g., [23andMe’s Bone Health Report]) can help assess genetic risk factors for adverse reactions.

Pharmaceutical distributors and healthcare systems should prepare for supply chain adjustments if GLP-1 agonists gain PMOS approval. Legal experts at firms like [Hogan Lovells’ Life Sciences Practice] are advising clients on regulatory compliance for off-label promotion, given the FDA’s recent crackdown on unapproved uses of semaglutide.

The Future: Will GLP-1 Agonists Become a Standard PMOS Therapy?

The next 18 months will be critical. If the GLYPHOS and BONE-SMA trials show statistically significant BMD improvements without excessive side effects, GLP-1 agonists could carve out a niche role in PMOS management, particularly for patients with high fracture risk and comorbidities (e.g., obesity, diabetes). However, cost remains a barrier: semaglutide’s annual price (~£5,000 in the UK) far exceeds bisphosphonates (~£200).

Dr. Chen predicts a two-tiered approach: “We’ll likely see GLP-1 drugs used as an adjunct therapy for high-risk patients, while bisphosphonates remain the backbone for most. The real innovation will come from combination therapies—perhaps GLP-1 agonists paired with anabolic agents like romosozumab.”

For now, patients must weigh individual risk vs. potential benefit. Those considering GLP-1 agonists for PMOS should:

• Seek care at [specialized osteoporosis clinics] with experience in metabolic bone disease.
• Enroll in [clinical trials] to contribute to long-term safety data.
• Monitor biomarkers (e.g., P1NP, CTX) through [certified bone health labs] like [LabCorp’s Bone Turnover Panel].

Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.